The abstract is read at the publisher; the summary is JClub's.
Black patients with active moderate-to-severe systemic lupus erythematosus in the BILAG-BR had lower odds of major clinical response after treatment escalation than White patients (OR 0·13, 95% CI 0·02–0·88).
- Why it matters: Ethnic differences in SLE outcomes are known, but evidence on how patients respond after treatment escalation across ethnic groups in UK practice has been limited.
- What they did: In a longitudinal cohort of 422 patients (≥16 years) from 64 UK secondary/tertiary centres, investigators assessed major clinical response at 6 and 12 months using mixed-effects logistic regression after rituximab or belimumab initiation within 12 months or immunosuppressive therapy within 1 month.
- The result: At 12 months, MCR was met by 10% of Black patients versus 24% of White patients, and fewer than a quarter overall achieved MCR, suggesting response disparities linked to baseline disease burden.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.